The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.d

Myocarditis (can be fulminant)

Publications

Li MT, He Y, Huang SY, Hu X, Chen JS

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.

Investigational new drugs 2024 Feb;42;116-126 — 2024 Feb — 116-126

Fazal M, Prentice DA, Kho LK, Fysh E

Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.

Internal medicine journal 2020 Aug;50;1003-1006 — 2020 Aug — 1003-1006

Yamaguchi S, Morimoto R, Okumura T, Yamashita Y, Haga T, Kuwayama T, Yokoi T, Hiraiwa H, Kondo T, Sugiura Y, Watanabe N, Kano N, Kohno K, Fukaya K, Sawamura A, Yokota K, Ishii H, Nakaguro M, Akiyama M, Murohara T

Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.

The Canadian journal of cardiology 2018 06;34;812.e1-812.e3 — 2018 06 — 812.e1-812.e3

Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM

Smoldering myocarditis following immune checkpoint blockade.

Journal for immunotherapy of cancer 2017 11 21;5;91 — 2017 11 21 — 91

Matson DR, Accola MA, Rehrauer WM, Corliss RF

Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab.

Journal of forensic sciences 2018 May;63;954-957 — 2018 May — 954-957

Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.

Neurology 2017 Sep 12;89;1127-1134 — 2017 Sep 12 — 1127-1134

Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohé C

Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.

Lung cancer (Amsterdam, Netherlands) 2016 09;99;117-9 — 2016 09 — 117-9

Gibson R, Delaune J, Szady A, Markham M

Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.

BMJ case reports 2016 Jul 20;2016; — 2016 Jul 20